Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Summary

This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in healthy participants and participants with sickle cell disease.

Timeline

Start

2020-02-05

Primary completion

2023-07-07

Completion

2023-07-07

Drugs

Indications